ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance

Share :
Published: 21 Mar 2023
Views: 3200
Rating:
Save
Prof Heather Payne and Dr Jochen Walz

Prof Heather Payne (University College Hospital, London, UK) and Dr Jochen Walz (Institut Paoli-Calmettes Cancer Centre, Marseille, France) discuss some of the quality of life data in prostate cancer reported at ASCO GU 2023.

They initially talk about the safety and quality of life analyses of apalutamide plus active surveillance versus active surveillance alone for low, and intermediate-risk prostate cancer. Prof Payne and Dr Walz then discuss the patients' perspective on fatigue and its management for advanced prostate cancer treated with androgen receptor inhibitors.

The study found that patients with advanced prostate cancer emphasised the lack of adequate knowledge and healthcare provider (HCP) recommendations for managing fatigue.

Prof Payne highlights that there is a need to develop recommendations for fatigue management and resources to support HCP's counselling methods to improve patient quality of life while on treatment.

Prof Payne and Dr Walz conclude by discussing the survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer treated with androgen receptor targeted therapies.
 

Safety and quality of life analyses of apalutamide plus active surveillance vs active surveillance alone for low, intermediate risk prostate cancer
Patient (pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs)
Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies
This programme is supported by an unrestricted educational grant from Janssen.